Leonard Nimoy’s widow warns smokers ‘you always think you have more time than you do’

Leonard Nimoy's widow Susan appeared in a new commercial for the CDC's Tips From Former Smokers campaign to warn others to quit before they come down with COPD like Nimoy did.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Authors: Ribaldone DG, Pellicano R, Actis GC Abstract An increasing deal of attention is being conveyed on the extra-intestinal manifestations of inflammatory bowel diseases (IBD). We compiled the present review in an attempt to upgrade the accuracy of the classification of such polymorphic entities. We focused on three patterns. First, the conventional extra-intestinal manifestations localized to bone and joints, to the eye, to the biliary tree and to the skin. Second, the so-called IBD-like syndromes accompanied by bone marrow-derived anomalies of innate or acquired immunity. Third, specific disorders of the skin...
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
This report highlights the presentation of a United States Army soldier who after a deployment was given a diagnosis of asthma, later found to have ILO and was subsequently diagnosed with concurrent EDAC. We follow up with a literature review and discussion of symptomatology, diagnosis, exercise bronchoscopy, and treatment modalities for both EDAC and ILO. PMID: 30989047 [PubMed]
Source: Respiratory Care - Category: Respiratory Medicine Authors: Tags: Respir Med Case Rep Source Type: research
Conclusions: In asthma and allergy, multimorbidity and polypharmacy are major concerns. Disease severity, drug use, and costs increased with multimorbid conditions. To reduce the burden, allergy management should be better integrated and more comprehensive.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research
COPD is a highly heterogeneous disease composed of different phenotypes with different aetiological and prognostic profiles and current classification systems do not fully capture this heterogeneity. In this s...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Research article Source Type: research
Impaired aerobic function is a potential mechanism of exercise intolerance in patients with combined cardiorespiratory disease. We investigated the pathophysiological and sensory consequences of a low change in oxygen uptake (V'O2)/change in work rate (WR) relationship during incremental exercise in patients with coexisting chronic obstructive pulmonary disease (COPD) and systolic heart failure (HF). After clinical stabilisation, 51 COPD–HF patients performed an incremental cardiopulmonary exercise test to symptom limitation. Cardiac output was non-invasively measured (impedance cardiography) in a subset of patients ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking Original Articles: COPD Source Type: research
Suissa and Ariel [1] performed a post hoc analysis of TRIBUTE and IMPACT [2, 3], by "digitising" the figures to obtain values over each month of the cumulative incidence curves. They concluded that the lower rate of a first exacerbation with triple long-acting muscarinic antagonist/long-acting β2-agonist/inhaled corticosteroid (LAMA/LABA/ICS) therapy was exclusively due to a lower rate in the first month of treatment, while the rates were comparable to LAMA/LABA in the subsequent 11 months. They argue that this pattern of "depletion of susceptible individuals" might identify a small group of p...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research
We thank A. Papi and co-workers for their letter on our examination of the recent single inhaler triple therapy trials. Their additional analyses provide further evidence for our interpretation that these trials provide significant opportunities for a precision medicine approach to chronic obstructive pulmonary disease (COPD) treatment [1].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research
Exercise limitation and exertional dyspnoea are common problems in patients with a variety of chronic lung diseases, as well as with heart failure. In chronic obstructive pulmonary disease (COPD) patients, the level of patient-reported dyspnoea is used as a parameter to assess COPD, currently leading to a "one size fits all" approach, largely based on pharmacological recommendations [1]. As exertional symptoms poorly correlate even with resting measurement lung function clusters [2], a more accurate estimate of functional capacity by cardiopulmonary exercise testing (CPET) can provide information about the influe...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
Authors: Skoczyński S, Minarowski Ł, Tobiczyk E, Oraczewska A, Glinka K, Ficek K, Mróz R, Barczyk A Abstract Respiratory failure is one of the most important risk factors for diagnostic bronchofiberoscopy (BF), whereas therapeutic bronchoscopies are typically performed in intubated patients. Only a few published studies analyzed the outcomes of noninvasive mechanical ventilation (NIV)-facilitated BF. In this case series, we present our experiences with NIV-facilitated diagnostic and therapeutic BF performed in patients with respiratory failure that was associated with acute interstitial pulmonary disease, ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
A recent FDA approval has one Triangle pharmaceutical company going head to head with the likes of pharma giants such as GSK – in a multi-billion dollar industry company officials believe they have the edge in. Circassia, a pharmaceutical company that calls Morrisville home to its U.S. headquarters, received FDA approval for Duaklir Pressair – a drug the treatment of patients with chronic obstructive pulmonary disea se (COPD). Circassia’s David Acheson, senior vice president of commercial…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: Chronic Obstructive Pulmonary | Health | Smokers